Bausch Health Reports Strong Q4 2025 Earnings with Strategic Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy BHC?
Source: seekingalpha
- Consistent Growth: Bausch Health achieved its 11th consecutive quarter of revenue and adjusted EBITDA growth, with full-year results exceeding guidance on all key metrics, demonstrating robust market performance and ongoing operational efficiencies.
- Strategic Acquisition: The company acquired Shibo, a full-service aesthetics distribution platform in China, on December 1, 2025, enhancing its direct commercial presence in one of the largest global aesthetics markets, which is expected to further boost market share and customer base.
- Financial Performance: Fourth-quarter revenue reached $1.391 billion, a 9% year-over-year increase, while adjusted EBITDA was $773 million, up 13%, reflecting strong performance in core products like Xifaxan and Thermage.
- Future Outlook: Management anticipates 2026 revenues between $5.25 billion and $5.4 billion, with adjusted EBITDA expected between $2.875 billion and $2.95 billion, indicating steady growth despite challenges from patent expirations and regulatory changes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BHC
Wall Street analysts forecast BHC stock price to rise
4 Analyst Rating
0 Buy
4 Hold
0 Sell
Hold
Current: 5.990
Low
7.00
Averages
8.25
High
10.00
Current: 5.990
Low
7.00
Averages
8.25
High
10.00
About BHC
Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bausch Health Reports Q4 2025 Earnings Miss
- Earnings Miss: Bausch Health's Q4 2025 financial results revealed a GAAP EPS of -$0.30, significantly below the expected $0.42, causing a ~4% drop in after-hours trading.
- Revenue Growth vs. Rising Expenses: The company reported revenue of approximately $2.8 billion, a 9.5% year-over-year increase that beat the consensus of $2.71 billion; however, a 16% YoY increase in expenses to ~$2.3 billion negatively impacted profitability.
- Positive Revenue Guidance: Bausch provided a 2026 revenue guidance of $10.625 billion to $10.875 billion, exceeding the consensus estimate of $10.52 billion, indicating confidence in future growth prospects.
- Improved Cash Position: By the end of 2025, Bausch's cash, cash equivalents, and restricted cash totaled $1.325 billion, up from $1.2 billion on December 31, 2024, reflecting better liquidity management.
See More
Bausch Health Reports Strong Q4 2025 Earnings with Strategic Acquisition
- Consistent Growth: Bausch Health achieved its 11th consecutive quarter of revenue and adjusted EBITDA growth, with full-year results exceeding guidance on all key metrics, demonstrating robust market performance and ongoing operational efficiencies.
- Strategic Acquisition: The company acquired Shibo, a full-service aesthetics distribution platform in China, on December 1, 2025, enhancing its direct commercial presence in one of the largest global aesthetics markets, which is expected to further boost market share and customer base.
- Financial Performance: Fourth-quarter revenue reached $1.391 billion, a 9% year-over-year increase, while adjusted EBITDA was $773 million, up 13%, reflecting strong performance in core products like Xifaxan and Thermage.
- Future Outlook: Management anticipates 2026 revenues between $5.25 billion and $5.4 billion, with adjusted EBITDA expected between $2.875 billion and $2.95 billion, indicating steady growth despite challenges from patent expirations and regulatory changes.
See More
Bausch Health (BHC) Q4 2025 Earnings Transcript
See More
Bausch Health Q4 2025 Earnings Highlights
- Sustained Growth: Bausch Health reported Q4 2025 revenue of $1.391 billion, a 9% year-over-year increase, reflecting strong performance across markets and further solidifying its position in the global pharmaceutical industry.
- Adjusted EBITDA Growth: Adjusted EBITDA reached $773 million, up 9% from the previous year, exceeding expectations and demonstrating effective management in cost control and growth investments, enhancing future financial flexibility.
- Strategic Acquisition: The acquisition of Shibo, a full-service aesthetics distribution platform in China in December 2025, strengthens direct commercial presence in the largest global aesthetics market, expected to drive future revenue growth and market share expansion.
- Debt Structure Optimization: Through a $1.7 billion debt exchange, Bausch Health significantly improved its debt maturity profile, enhancing financial stability and providing greater flexibility for future business development.
See More
Bausch Health Companies Reports Disappointing Q4 and Full-Year 2025 Results
- Disappointing Earnings: Bausch Health Companies reported a Q4 non-GAAP EPS of $0.32, missing estimates by $0.94, indicating significant challenges in profitability that may undermine investor confidence.
- Revenue Decline: The Q4 revenue of $1.40 billion fell short of the $1.31 billion expectation, reflecting weak market demand that could exert ongoing pressure on future financial performance.
- Annual Performance: For the full year 2025, revenue reached $5.101 billion with a GAAP net loss of $360 million; despite a 6% year-over-year revenue growth, the overall financial health remains fragile, necessitating close monitoring of future profitability.
- Future Guidance: Bausch Health anticipates 2026 full-year revenue between $5.375 billion and $5.475 billion, projecting a 5%-7% constant currency growth; however, market sentiment remains cautious regarding the company's ability to meet these targets.
See More
Bausch Health Q4 Earnings Announcement Scheduled
- Earnings Release Date: Bausch Health Companies (BHC) is set to announce its Q4 earnings on February 18th after market close, with consensus EPS estimated at $1.26 and revenue expected to reach $2.71 billion, reflecting a 5.9% year-over-year growth.
- Earnings Estimate Changes: Over the last three months, EPS estimates have seen no upward revisions but two downward adjustments, indicating a cautious market sentiment regarding the company's profitability, which could impact investor confidence.
- Revenue Estimate Adjustments: Similarly, revenue estimates have also experienced two downward revisions without any upward adjustments, reflecting market concerns about Bausch Health's future performance, potentially leading to stock price volatility.
- Market Reaction: Bausch Health has faced pressure recently due to the failure of a drug in development, particularly the absence of a successor to Xifaxan, which may affect investor perceptions of the company's long-term growth prospects.
See More
Bausch Health Reports Q4 2025 Earnings Miss
- Earnings Miss: Bausch Health's Q4 2025 financial results revealed a GAAP EPS of -$0.30, significantly below the expected $0.42, causing a ~4% drop in after-hours trading.
- Revenue Growth vs. Rising Expenses: The company reported revenue of approximately $2.8 billion, a 9.5% year-over-year increase that beat the consensus of $2.71 billion; however, a 16% YoY increase in expenses to ~$2.3 billion negatively impacted profitability.
- Positive Revenue Guidance: Bausch provided a 2026 revenue guidance of $10.625 billion to $10.875 billion, exceeding the consensus estimate of $10.52 billion, indicating confidence in future growth prospects.
- Improved Cash Position: By the end of 2025, Bausch's cash, cash equivalents, and restricted cash totaled $1.325 billion, up from $1.2 billion on December 31, 2024, reflecting better liquidity management.
See More
Bausch Health Reports Strong Q4 2025 Earnings with Strategic Acquisition
- Consistent Growth: Bausch Health achieved its 11th consecutive quarter of revenue and adjusted EBITDA growth, with full-year results exceeding guidance on all key metrics, demonstrating robust market performance and ongoing operational efficiencies.
- Strategic Acquisition: The company acquired Shibo, a full-service aesthetics distribution platform in China, on December 1, 2025, enhancing its direct commercial presence in one of the largest global aesthetics markets, which is expected to further boost market share and customer base.
- Financial Performance: Fourth-quarter revenue reached $1.391 billion, a 9% year-over-year increase, while adjusted EBITDA was $773 million, up 13%, reflecting strong performance in core products like Xifaxan and Thermage.
- Future Outlook: Management anticipates 2026 revenues between $5.25 billion and $5.4 billion, with adjusted EBITDA expected between $2.875 billion and $2.95 billion, indicating steady growth despite challenges from patent expirations and regulatory changes.
See More
Bausch Health (BHC) Q4 2025 Earnings Transcript
See More
Bausch Health Q4 2025 Earnings Highlights
- Sustained Growth: Bausch Health reported Q4 2025 revenue of $1.391 billion, a 9% year-over-year increase, reflecting strong performance across markets and further solidifying its position in the global pharmaceutical industry.
- Adjusted EBITDA Growth: Adjusted EBITDA reached $773 million, up 9% from the previous year, exceeding expectations and demonstrating effective management in cost control and growth investments, enhancing future financial flexibility.
- Strategic Acquisition: The acquisition of Shibo, a full-service aesthetics distribution platform in China in December 2025, strengthens direct commercial presence in the largest global aesthetics market, expected to drive future revenue growth and market share expansion.
- Debt Structure Optimization: Through a $1.7 billion debt exchange, Bausch Health significantly improved its debt maturity profile, enhancing financial stability and providing greater flexibility for future business development.
See More
Bausch Health Companies Reports Disappointing Q4 and Full-Year 2025 Results
- Disappointing Earnings: Bausch Health Companies reported a Q4 non-GAAP EPS of $0.32, missing estimates by $0.94, indicating significant challenges in profitability that may undermine investor confidence.
- Revenue Decline: The Q4 revenue of $1.40 billion fell short of the $1.31 billion expectation, reflecting weak market demand that could exert ongoing pressure on future financial performance.
- Annual Performance: For the full year 2025, revenue reached $5.101 billion with a GAAP net loss of $360 million; despite a 6% year-over-year revenue growth, the overall financial health remains fragile, necessitating close monitoring of future profitability.
- Future Guidance: Bausch Health anticipates 2026 full-year revenue between $5.375 billion and $5.475 billion, projecting a 5%-7% constant currency growth; however, market sentiment remains cautious regarding the company's ability to meet these targets.
See More
Bausch Health Q4 Earnings Announcement Scheduled
- Earnings Release Date: Bausch Health Companies (BHC) is set to announce its Q4 earnings on February 18th after market close, with consensus EPS estimated at $1.26 and revenue expected to reach $2.71 billion, reflecting a 5.9% year-over-year growth.
- Earnings Estimate Changes: Over the last three months, EPS estimates have seen no upward revisions but two downward adjustments, indicating a cautious market sentiment regarding the company's profitability, which could impact investor confidence.
- Revenue Estimate Adjustments: Similarly, revenue estimates have also experienced two downward revisions without any upward adjustments, reflecting market concerns about Bausch Health's future performance, potentially leading to stock price volatility.
- Market Reaction: Bausch Health has faced pressure recently due to the failure of a drug in development, particularly the absence of a successor to Xifaxan, which may affect investor perceptions of the company's long-term growth prospects.
See More
